Introduction
============

The number of patients suffering from chronic kidney disease is rapidly growing worldwide, with increasing incidence, prevalence and progressiveness resulting in end-stage renal disease (ESRD) ([@b1-etm-0-0-7183]). Kidney transplantation is the most effective treatment for ESRD ([@b2-etm-0-0-7183]). In 1954, a team headed by Murray ushered in the modern era of organ transplantation with the first successful human organ transplantation between two identical twins ([@b3-etm-0-0-7183]). Scholars then began to explore kidney transplantation and experiments revealed that successful kidney transplantation may significantly improve the quality of life for patients with ESRD. Advances in immunosuppression over the last three decades have led to vast improvements in the control of acute rejection and short-term graft survival in kidney transplant patients ([@b4-etm-0-0-7183]). However, no significant improvements in long-term outcomes have been achieved, and concerns over the morbidity of lifelong regimens of immunosuppressive drugs remain. Analysis using the Kaplan-Meier method indicated a cumulative probability of graft survival at 1, 3, 5, 7 and 10 years of 99.1, 97.7, 94.3, 85.7 and 62.1%, respectively ([@b5-etm-0-0-7183]). Acute rejection is the major cause of kidney transplant loss and an independent risk factor affecting kidney function and long-term survival, which are dependent on immune rejection and the side effects of immunosuppressive regimens ([@b6-etm-0-0-7183]). Following kidney transplantation, immunosuppressants are used to prevent graft rejection, which greatly enhances the probability of survival of the transplant ([@b7-etm-0-0-7183]). However, since the rejection process is difficult to reverse once the typical clinical symptoms occur, the prevention and reduction of early acute rejection is conducive to transplant recipients.

The rejection of kidney transplants is essentially an immune response. Cellular immunity is the core factor for transplant immunization. The immune cells of the recipient attack the transplanted kidney directly or indirectly by releasing a large amount of various cytokines. Concerning the particular cell types involved, several studies have discussed the role of T-cell receptors (TCRs) in transplant rejection. Velásquez *et al* ([@b8-etm-0-0-7183]) suggested that differential expression of particular TCR β chain variable families and high levels of circulating CD4(+) CD25 (high) T cells in long-term surviving renal transplant patients contribute to an active and specific state of immunologic suppression. Matsutani *et al* ([@b9-etm-0-0-7183]) indicated that the skew in TCR usage was correlated with the levels of clonal T-cell expansion, indicating that the expanding T cells were responsible for the skew in TCR usage. These results demonstrate that clonal T-cell expansion in the periphery has a negative impact on long-term graft function. In addition, a previous study by our group on TCR after kidney transplantation indicated that the TCR repertoire diversity of transplantation groups was relatively lower compared with that in the NC group ([@b10-etm-0-0-7183]). The diversity of TCRs, B-cell receptors (BCRs) and secreted antibodies makes up the core of the complex immune system, and they serve as pivotal defensive components to protect the body against invading pathogens, including viruses and bacteria ([@b11-etm-0-0-7183]). However, the changes in B cells and BCRs in patients with acute rejection after kidney transplantation at the molecular level remain to be determined and their role in the underlying pathological process requires to be investigated. BCR antigens (Ags) are formed through the rearrangement of the immunoglobulin (Ig) heavy chain (IGH) variable (IGHV), IGH diversity (IGHD) and IGH joining (IGHJ) gene segments of the complementarity-determining region 3 (H-CDR3) of the BCR. CDR3 is the most hyper-variable region in the BCR and the most important structure in Ag recognition, as it determines the fate of developing and responding lymphocytes ([@b12-etm-0-0-7183]), which provides the most important structural basis for Ag binding. CDR3 is the product of multiple VDJ gene rearrangements and multiple non-coding N nucleotide insertions.

In the present study, the IGH of the CDR3 region of BCR was assessed in peripheral blood mononuclear cells (PBMCs) of 3 cases of typical acute rejection after kidney transplantation by using high-throughput sequencing. Comparative CDR3 diversity and length distribution analyses were performed and the IGHD, IGHJ and IGHV gene family expression as well as the IGHV-IGHJ family distribution were assessed. In addition, the Shannon entropy (SE), highly expanded clone (HEC) distributions, Simpson\'s diversity (SD) index and the Gini coefficient for the diversity and molecular expression of the IGH of the CDR3 region of BCR were calculated and analyzed. The present study enhances the current understanding of the balance between immunodeficiency and immune oversuppression in kidney transplant recipients. It provides knowledge to guide the individualized and rational use of immunosuppressive agents for preventing acute rejection or infection in renal transplant recipients.

Patients and methods
====================

### Patients and controls

With the widespread use of various novel immunosuppressive agents, the incidence of acute rejection has decreased in recent years, therefore, 3 cases encountered over 1.5 years were included in the current study ([@b13-etm-0-0-7183]). The study assessed 3 patients with typical acute rejection after kidney transplantation. Following obtainment of informed consent and in accordance with a protocol approved by the Ethics Committee of Guangxi Key Laboratory of Metabolic Disease Research (Guilin, China), a total of 3.5 ml peripheral blood was drawn from 3 typical patients \[post-operative renal function and normal recovery within two weeks of acute rejection; pathological examination results and diagnostic criteria in line with the Baff classification of acute rejection ([@b14-etm-0-0-7183])\] at Guilin No. 924 Hospital (Guilin, China) between October 2014 and June 2016. Samples were collected 1 day prior to kidney transplantation (Pre1), 1 day after kidney transplantation (Post1) and 7 days after kidney transplantation (Post7). These samples were collected from one female patient aged 51 years (Case 1; weight, 54 kg), one female patient aged 47 years (Case 2; weight, 51 kg) and one male patient aged 61 years (Case 3; weight, 63 kg). The clinicopathological characteristics of the patients are listed in [Table I](#tI-etm-0-0-7183){ref-type="table"}. The treatment of each of the patients prior to and after transplantation/rejection is summarized in [Table II](#tII-etm-0-0-7183){ref-type="table"}.

### B-cell isolation and DNA extraction

Ficoll lymphocyte separation medium (cat. no. MD-YSZ707; Mei De Biotechnology Co., Ltd., Tianjin, China) and density gradient centrifugation were used to separate peripheral mononuclear cells from the blood obtained at different time points (Pre1, Post1 and Post7). The PBMCs of each patient were separated from the blood obtained at the different time-points. A QIAamp DNA Mini kit (cat. no. 51304; Qiagen, Hilden, Germany) was used to extract genomic DNA from 9 peripheral blood samples of the 3 patients, which was stored at −20°C.

### Multiplex polymerase chain reaction (PCR) amplification of the BCR H-CDR3 region

DNA samples (500 ng; minimum concentration of no less than 35 ng/µl) were obtained from each patient. Specifically designed V-region primers and J-region primers were used. Multiplex PCR was performed with the Qiagen multiplex PCR kit (cat. no. Y5-206145; Qiagen). The 12 forward primers and 4 reverse primers utilized were used for multiplex PCR to amplify the rearranged H-CDR3 region ([Table III](#tIII-etm-0-0-7183){ref-type="table"}). High fidelity enzyme was used for multiplex PCR (Qiagen Multiplex PCR kit; Qiagen). For each sample, the same amount of DNA was used for multiplex PCR. The PCR conditions were set as 95°C for 15 min, followed by 25 cycles of 94°C for 15 sec and 60°C for 3 min, with a final extension at 72°C for 10 min. PCR was performed using the ProFlex™ PCR machine (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and the PCR products were purified by AMPure XP beads (Beckman Coulter, Brea, CA, USA) to remove primer sequences. A second round of PCR was performed to add a sequencing index to each sample. The PCR conditions were set as 98°C for 1 min, followed by 25 cycles of 98°C for 20 sec, 65°C for 30 sec and 72°C for 30 sec, with a final extension at 72°C for 5 min. The library was separated on agarose gel and the target region was isolated and cleaned using QIAquick Gel Extraction kits (cat. no. Y5-28704; Qiagen). A total of 5 µl DNA sample was mixed with the appropriate amount of bromophenol blue indicator spotting buffer for electrophoresis. Subsequently, 3 µl DNA marker and 0.7% agarose gel were added. Electrophoresis was performed for 40 min at 150 volts (large electrophoresis tank); electrophoresis to bromophenol blue migrated for a suitable distance in the gel. The gel was removed and the ethidium bromide color was checked, followed by capturing of images under ultraviolet light.

Electrophoresis was performed to recover 100--190 bp multiplex PCR products using a QIAquick Gel Extraction kit (Qiagen). End Repair Mix (Sangon Biotech Co., Ltd., Shanghai, China) was added and the terminal repair reaction was performed at 20°C, in accordance with the manufacturer\'s protocol, followed by purification (cat. no. Y5-28106; QIAquick PCR Purification kit; Qiagen). The DNA fragment obtained after the terminal repair was attached to the 'A' base at its 3′ end. The adapter was ligated with Adapter oligo mix and DNA ligase. The linker-modified DNA fragment was enriched by PCR and subsequently, the PCR products were subjected to agarose gel electrophoresis. After the target fragment was excised from the gel, the QIAquick Gel Extraction kit (Qiagen) was used for gel purification and the fragment containing the PCR product dissolved in Elution Buffer (provided by the Gel Extraction kit). The library was then constructed.

### High-throughput sequencing

High-throughput sequencing approaches to study BCR repertoires may be used to measure the diversity of B-cell populations ([@b15-etm-0-0-7183]). For high-throughput sequencing, each sample must be prepared in the same manner, containing 2 µg total DNA. Multiplex PCR with a mixture of primers targeted the rearranged V and J segments to represent receptor diversity ([@b16-etm-0-0-7183]). Multiplex PCR amplification was performed to amplify rearranged CDR3 sequences. An upstream primer and downstream primer in the IGHV functional gene region and IGHJ functional gene region were designed. Each primer was specific for a particular site of the H-CDR3 of BCR. Using the Illumina HiSeq 2000 sequencing platform (Illumina, Inc., San Diego, CA, USA) to perform the sequencing of PCR products, NaOH was added and samples were diluted to a certain concentration according to the expected amount of data obtained with the machine. The library was added to FlowCell (part of the Illumina Hiseq 2000 platform) after denaturation and dilution. PCR-bridged amplification was performed using the reagent TruSeq PE Cluster kit v3-cBot-HS (cat. no. PE-401-3001; Illumina, Inc.) on the cluster generation platform cBot. Finally, the prepared Flow Cell was sequenced with the HiSeq 2000 sequencing system and the reagent TruSeq SBS KIT-HS v3 (FC-401-3001; both Illumina, Inc.).

### Bioinformatics analysis

Raw sequences in the FASTQ format were processed using the Basic Local Alignment Search Tool (BLAST) online software (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). PCR products were sequenced using an Illumina Genome Analyzer and the sequences were scored and filtered with the subsequent formula. Firstly the sequences with connectors were filtered out and the reads with an average quality score \<15 (Illumina 0--40 quality system) were removed. For unknown bases (N bases), the quantity was ≤5%. Regarding the sequences at the tail with low quality, those with a score \<10 were removed to ensure the average quality score of sequences was \>15 and the length of remaining sequences were \>60 nt following filtration. With the above filtration steps, clean data was generated. Two Pair-end (PE) sequences from clean data were merged into a contig sequence in two steps: i) By aligning the tail parts of two sequences and assessing the identity \[COPEv1.1.3 software; Bureau Gravimetrique International (BGI), Toulouse, France\] with at least 10 bases of overlap required and the overlapping section having 90% base match; ii) as different primers may result in sequences of different lengths, the short certain products (\<100 bp) were merged by aligning the head part of the sequence (FqMerger software; BGI). Using this method, the merged contig sequences and the length of the distribution plot were obtained.

### Statistical analysis

The statistical analyses were performed with GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA), and the Student\'s t-test was used with Bonferroni correction. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Sequencing

Using high-throughput sequencing (Illumina Genome Analyzer), BCR H-CDR3 repertoires were sequenced from B cells isolated from the PBMCs of 3 kidney transplant patients with acute rejection by obtaining an average of 401967.4 total raw reads per sample. After filtering and removing adaptor sequences, contamination and low-quality reads, an average of 369,389.9 reads that met the quality requirements were collected. The sequence statistics for each sample after comparison and statistical analysis are provided in [Table IV](#tIV-etm-0-0-7183){ref-type="table"}.

### Diversity evaluation of the BCR repertoire

To evaluate the diversity of the BCR repertoire, the SE, SD, the Gini coefficient and HEC distributions were determined at the three different time-points ([Fig. 1](#f1-etm-0-0-7183){ref-type="fig"}). SE is a measure of diversity in the immune repertoire, with a value closer to 1 indicating a higher diversity. The SE for Case 1, 2 and 3 was 0.620, 0.645 and 0.592, respectively, at Pre1, 0.504, 0.547 and 0.563, respectively, at Post1, and 0.644, 0.615 and 0.549, respectively, at Post7. The SE at Pre1 was significantly lower than that at Post1 (P=0.0267). The SD index may be used to describe the diversity of the clone type of the BCR H-CDR3 in each patient at different time-points, which a larger index indicating a greater diversity. The SD index for Case 1, 2 and 3 at Pre1 was 0.9984, 0.9991 and 0.9974, respectively, that at Post1 was 0.9885, 0.9947 and 0.9966, respectively and that at Post7 was 0.9984, 0.9979 and 0.9952 respectively. The Gini coefficient is used to measure the heterogeneity of different clone types, with 1 indicating only one clone and 0 indicating the same frequency of all clones in the samples. At Pre1, the Gini coefficient for Case 1, 2 and 3 was 0.838, 0.828 and 0.848, respectively, that at Post1 was 0.877, 0.868 and 0.868, respectively, and that at Post7 was 0.813, 0.834 and 0.872, respectively. The Gini coefficient at Post1 was significantly lower than that at Pre1 (P=0.0164). The HEC ratio is defined as the expression of a certain CDR3 sequence exceeding 0.5% of the total CDR3 sequence. At Pre1, the HEC ratio for Case 1, 2 and 3 was 0.088, 0.017 and 0.190, respectively, that at Post1 was 0.547, 0.363 and 0.239, respectively and that at Post7 was 0.080, 0.109 and 0.302, respectively. [Fig. 1](#f1-etm-0-0-7183){ref-type="fig"} indicates that the initial diversity of the BCR repertoire of Case 1 and 2 was higher at Pre1, decreased at Post1 and then increased at Post7. That of Case 3 was lower at Pre1 and then decreased after transplantation. From the results, the current study hypothesized that the pre-operative induction drugs and surgical trauma increased the HEC number and reduced the immune diversity of CDR3. With the recovery of immune function after transplantation, or the assumed lack of withdrawal immunosuppression, the number and ratio of HECs decreased in the patients and then increased.

### Analysis of IGHD, IGHJ and IGHV gene families

Ig gene sequences have recently gained significance in clinical decision-making. To evaluate changes in the IGHD, IGHJ and IGHV gene frequencies of the three patients over time, the frequencies were calculated at different time-points. As indicated in [Figs. 2](#f2-etm-0-0-7183){ref-type="fig"}, [3](#f3-etm-0-0-7183){ref-type="fig"} and [4](#f4-etm-0-0-7183){ref-type="fig"}, respectively, the IGHD, IGHJ and IGHV gene family distributions of the patients have different expressions levels at each time-point. [Fig. 5](#f5-etm-0-0-7183){ref-type="fig"} indicates that the BCR repertoire of the IGHV gene family was altered after transplantation. For instance, Case 1 lost IGHV3-22, IGHV3-49, IGHV3/OR16-10, IGHV4-28 and IGHV4-55 after transplantation. Case 2 gained new IGHV usage at a low frequency, including IGHV3-64D and IGHV3-72. Case 3 gained new IGHV usage, IGHV1-69-2 at Post1 and IGHV1/OR15-4 and IGHV3-72 at Post7, while he lost IGHV3-64D and IGHV3/OR16-8 at Post7. Of note, these gene changes were all within the IGHV3 family. The usage frequency of the IGHD and IGHV gene families was also analyzed, and it was assessed which genes were upregulated and downregulated. At Post1, IGHV3/OR was significantly upregulated (P=0.0474), while IGHD3-9 was significantly downregulated (P=0.0437). At Post7, IGHV3-21 was significantly upregulated (P=0.0328), and IGHD2-15 and IGHV1-45 were significantly downregulated (P=0.0456 and 0.0143, respectively). Heat maps detailing the differential expression of the genes among the different patients at different time-points are presented in [Fig. 6](#f6-etm-0-0-7183){ref-type="fig"}, while those for IGHJ are provided in [Fig. 7](#f7-etm-0-0-7183){ref-type="fig"} and those for the IGHV gene family in [Fig. 8](#f8-etm-0-0-7183){ref-type="fig"}.

### Pairing of IGHV-IGHJ genes

To assess changes in IGHV-IGHJ gene pairing over time, the frequency of IGHV-IGHJ pairing was calculated for the three time-points. The heat map in [Fig. 9](#f9-etm-0-0-7183){ref-type="fig"} indicates that IGHV-IGHJ gene pairing in the three patients was not markedly changed at the three time-points. It is worth noting that all 3 cases had a similar dominant pairing. Different colors represent different IGHJ genes, and the size of the circles represents the level of expression. The genes that exhibited high expression levels included IGHJ6-IGHV3-11, IGHJ4-IGHV3-11, IGHJ6-IGHV3-30, IGHJ4-IGHV3-30 and IGHJ6-IGHV5-51.

### Length distribution of H-CDR3

The change in composition of unique H-CDR3 over time, including H-CDR3 length distribution and H-CDR3 amino acid (AA) usage, was then assessed. The change in H-CDR3 length distribution in the 3 patients is provided in [Figs. 10](#f10-etm-0-0-7183){ref-type="fig"}--[12](#f12-etm-0-0-7183){ref-type="fig"}. The length of CDR3 in healthy people should be similar to the gaussian distribution. Where R^2^ is the fitting value of gaussian distribution, R^2^ is the closer to 1 and the value is the closer to the gaussian distribution. For the H-CDR3 length distribution of Case 1, the R^2^ value at Pre1, Post1 and Post7 was 0.9501, 0.7126 and 0.9268, respectively. The AA usage of unique H-CDR3 in Case 1 was 17 and 14 AA at Pre1, 14, 15 and 18 AA at Post1 and 16 AA at Post7 ([Fig. 10](#f10-etm-0-0-7183){ref-type="fig"}). For the H-CDR3 length distribution of Case 2, the R^2^ value at Pre1, Post1 and Post7 was 0.9774, 0.7401 and 0.9307, respectively ([Fig. 11](#f11-etm-0-0-7183){ref-type="fig"}). The AA usage of unique H-CDR3 for Case 2 was 13, 14 and 18AA at Pre1, 14 and 15 AA at Post1 and 13, 15 and 16 AA at Post7. The CDR3 length distribution of Case 1 was similar to that of Case 2. The diversity of the BCR repertoire was the highest at Pre1 and the lowest at Post1, and was then increased again at Post7, but not to the pre-operative level. For the H-CDR3 length distribution of Case 3, the R^2^ value at Pre1, Post1 and Post7 was 0.9405, 0.9146 and 0.9038 ([Fig. 12](#f12-etm-0-0-7183){ref-type="fig"}). The AA usage of unique H-CDR3 for Case 3 was 12 and 13AA at Pre1, 14--16 AA at Post1 and 15AA at Post7. The diversity of the BCR repertoire of Case 3 did not change significantly.

Discussion
==========

B cells represent a major component of the cellular immune system. Acute rejection after kidney transplantation is mainly caused by cellular immunity and is reversible in a large proportion of cases. When rejection occurs, the patient produces a large number of cytotoxic T cells, which then kill their target cells directly, and furthermore, the patient\'s T cells help to activate lymphokines to then promote the differentiation of B-cells, which produce antibodies against the graft, ultimately leading to acute rejection after kidney transplantation ([@b17-etm-0-0-7183]). Certain studies conclude that B-cell diversity exhibits a marked decrease with age, and B-cell immune frailty is also a marker of general frailty ([@b18-etm-0-0-7183]). Patients with Omenn syndrome have a high proportion of class-switched IHC transcripts and an increased somatic hypermutation rate, suggesting *in vivo* activation of these B cells ([@b19-etm-0-0-7183]). The BCR is an indispensable functional receptor for B cells and its diversity ensures that B cells are able to respond to a variety of different Ags. B cells also participate in the anti-inflammatory response and tolerance induction ([@b20-etm-0-0-7183]). Studies have indicated that in addition to its association with the clinical and phenotypic presentation, renal allograft tolerance is highly associated with the B-cell signature. Newell *et al* ([@b21-etm-0-0-7183]) demonstrated that the regulation of cellular immunity is a critical role for B cells and provided a set of candidate genes for the wider-scale screening of kidney transplant recipients.

Characterization of Ag-specific BCR repertoires is essential for understanding disease mechanisms involving humoral immunity. A study by Ma *et al* ([@b22-etm-0-0-7183]) suggests that the mechanism of high-frequency CDR3 generation is associated with the maturation of IgG affinity (somatic hypermutation) during the recombinant HBV vaccine-induced B-lymphocyte responses. In the present study, using high-throughput sequencing, the BCR H-CDR3 region was analyzed in the DNA from PBMCs of 3 kidney transplant patients with typical acute rejection after kidney transplantation. The results suggested that the diversity of the BCR repertoire in patients was the highest at Pre1, while it was the lowest at Post1, which may be due to the induction of immunosuppressive agents and the effect of surgical trauma. The diversity increased again at Post7 but failed to achieve pre-transplantation levels before acute rejection occurred. It may be hypothesized that the number of Ig subtypes increased in patients after kidney transplantation.

The present study comprehensively analyzed the IGHD, IGHJ and IGHV gene family distribution and the frequency of IGHV-IGHJ gene pairing. The results suggested that the IGHV3-22, IGHV3-49, IGHV3/OR16-10, IGHV4-28, IGHV4-55, IGHV3-64D and IGHV3/OR16-8 genes were lost from the IGHV gene family. In addition, the newly formed IGHV3-72, IGHV1-69-2 and IGHV1/OR15-4 genes were expressed at low levels. Among the lost genes identified in the present study, the IGHV gene family was also reported in other studies. A study by Roy *et al* ([@b23-etm-0-0-7183]) revealed features of a disease- and Ag-specific autoantibody repertoire with preferred paired H chain V region and L chain V region usage and pairings, limited mutations, molecular dominance and selection of particular CDR3 sequences. According to individual gene segments of kidney transplantation patients divided into different groups, blood group ABO-incompatible patients with accommodation (ABOiA), ABO-compatible stable patients (ABOcS), and ABO-incompatible patients with biopsy-proven acute antibody-mediated rejection (ABOiR), gene segments of IGHV3, IGKV1, IGLV2 and IGLJ3 were most frequently used in all groups, while IGHV3-7, IGHV3-15, IGHV4-59, IGKV3-11, IGLV1-44, IGLV2-14, IGLV4-69 and IGLV7-46 were more frequently used in the ABOcS group than in the other groups, and IGKV3-7 was more frequently used in the ABOiR group than in the other groups. IGLV5-52 and IGLV7-43 were more frequently used in the ABOiA group than in the ABOcS group ([@b24-etm-0-0-7183]). The BCR repertoires of systemic lupus erythematosus patients lost a certain amount of IGHV gene usage after high-dose glucocorticoid treatment ([@b25-etm-0-0-7183]). IGHV genes from the IGHV3 superfamily encode antibodies against the D Ag ([@b26-etm-0-0-7183]). It is presumed that B-cell expansion against allogeneic Ags prior to the occurrence of acute rejection leads to the production of these abnormally expressed genes, with highly expanded clones disrupting the diversity of the CDR3 region. The three patients of the present study had a similar dominant IGHV-IGHJ gene pairing (IGHJ6-IGHV3-11, IGHJ4-IGHV3-11, IGHJ6-IGHV3-30, IGHJ4-IGHV3-30 and IGHJ6-IGHV5-51), suggesting that the rejection in the patients may be associated with the auto-Ag that is induced. A previous study by our group on the T-cell repertoire following kidney transplantation determined by high-throughput sequencing revealed that that the length of CDR3 varied from 16 to 106 nt, and the 5 most frequently observed CDR3 lengths were 42, 45, 39, 36 and 48 nt. The 5 most frequently observed VD indel lengths were 0, 2, 3, 1 and 4 nt. The 5 most commonly observed DJ indel lengths were 4, 0, 3, 1 and 2 nt ([@b10-etm-0-0-7183]). The results of the length distribution analysis of H-CDR3 suggested a similar length (14--18 AA) among the three patients. The length distribution at Pre1 and Post7 tended to be consistent with a normal distribution pattern. However, at Post1, a skewed distribution was observed. The length distribution of CDR3 in Case 3 was stable at 12--16 AA and tended to exhibit a normal distribution pattern. These results suggest that the length distribution of H-CDR3 may change after kidney transplantation, but the specific AA sites require to be determined. Whether these observed changes in IGHV genes and IGHD genes may serve as better markers in B-cell immunology requires further investigation. The study by Beausang *et al* ([@b27-etm-0-0-7183]) suggested that subjects that responded to de-sensitization therapy had pre-treatment repertoires composed of a larger fraction of class-switched (IgG and IgA) isotypes compared to non-responding candidates, indicating that the measurement of B-cell repertoires may be applied to identify candidates that respond to de-sensitization therapy. In the present study, three patients with acute rejection after kidney transplantation were assessed for the purpose of performing a composition and diversity analysis of the BCR H-CDR3 repertoire. The next step will be to assess the association of the repertoire with clinical conditions. The study of de-sensitization therapy for renal transplant patients is a promising field.

Due to the limited sample size of the present study, most differences were not observed to reach statistical significance. The small sample size is a limitation of the present study, and therefore, more samples should be included in follow-up studies to reach statistical significance. The association of the variation of the BCR H-CDR3 repertoire with clinical outcomes in kidney transplantation patients should also be explored. This may offer potential guidance for individualized treatment with immunosuppressive agents and contribute to the improvement of the short- and long-term survival of kidney transplant recipients.

Traditional sequencing and cloning methods only generate a small amount of sequence information on BCR dominant clones; it is difficult to obtain individual BCR sequence library information, and it is impossible to evaluate the immune status. Using high-throughput sequencing, a large number of BCR sequences in kidney transplant patients may be obtained from a small amount of peripheral blood, and the BCR dominant clones as well as quantitative indicators, including the SE and the diversity of the BCR, may be determined. Furthermore, changes in BCR CDR3 diversity may be observed in patients with acute rejection after renal transplantation in order to investigate its potential clinical application for early detection of acute rejection. In future studies, the utility of dynamic monitoring of BCR CDR3 should be verified by prospective analyses and comparisons. BCR CDR3 diversity helps to determine the patient\'s immune status following transplantation and is instructive for applying the correct treatment regimen.
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![Change in the composition of unique H-CDR3 over time, including H-CDR3 length distribution and H-CDR3 AA usage of Case 2. H-CDR3, immunoglobulin heavy chain complementarity-determining region 3; AA, amino acids; Pre1, 1 day prior to transplantation; post7, 7 days post transplantation.](etm-17-03-2206-g10){#f11-etm-0-0-7183}

![Change in the composition of unique H-CDR3 over time, including H-CDR3 length distribution and H-CDR3 AA usage of Case 3. H-CDR3, immunoglobulin heavy chain complementarity-determining region 3; AA, amino acids; Pre1, 1 day prior to transplantation; post7, 7 days post transplantation.](etm-17-03-2206-g11){#f12-etm-0-0-7183}

###### 

Clinicopathological characteristics of the patients.

  Case no.   Sex      Age (years)   Time-point   Temperature (°C)   Urinary volume (ml)   Urine protein (g/l)   Creatinine (µmol/l)   Lymphocytes (109/l)   Tacrolimus (ng/ml)
  ---------- -------- ------------- ------------ ------------------ --------------------- --------------------- --------------------- --------------------- --------------------
  1                                 Pre1         36.4               6,710                 1+                    223                   0.05                  /
             Female   51            Post1        37.2               4,300                 1+                    112                   0.09                  /
                                    Post7        36.8               3,700                 1+                    108                   0.07                  4.3
  2                                 Pre1         36.0               2,050                 /                     454                   1.59                  /
             Female   47            Post1        36.0               6,560                 1+                    549                   0.14                  /
                                    Post7        36.5               2,500                 +/−                   156                   0.14                  9.0
  3                                 Pre1         36.5               4,260                 1+                    1,925                 1.16                  /
             Male     61            Post1        36.0               5,820                 +/−                   530                   0.23                  /
                                    Post7        36.3               3,980                 +/−                   81                    /                     6.3

Pre1, 1 day prior to transplantation; post7, 7 days post transplantation.

###### 

Response to therapy in the patients.

  Case no.   Pre-operative management of renal dysfunction   Post-operative and prior to acute rejection medication intravenous drip   Oral medication (post-operative and prior to acute rejection)   Following acute rejection medication administration via intravenous drip
  ---------- ----------------------------------------------- ------------------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------------------
  1          Hemodialysis                                    Anti-human T Lymphocyte Porcine Immunoglobulin                            Tacrolimus (3.5 mg, 2 times/day)                                Methylprednisolone (500 mg/day, 2 days)
                                                             (Surgery and post1-2, 500 mg/day; post3-7, 250 mg/day)                    Mycophenolate sodium enteric-coated                             Anti-human T Lymphocyte Porcine
                                                             Methylprednisolone (Surgery and post1-2, 500 mg/day)                      tablets (360 mg, 2 times/day)                                   Immunoglobulin (500 mg/day, 5 days)
                                                             Mycophenolate mofetil (Post1-2, 1,000 mg, 2 times/day)                    Methylprednisolone (8 mg/day)                                   
  2          Hemodialysis                                    Anti-human T Lymphocyte Rabbit Immunoglobulin                             Tacrolimus (3.0 mg morning, 3.5 mg night)                       Anti-human T Lymphocyte Rabbit
                                                             (Surgery and post1-2, 500 mg/day; post3-7, 250 mg/day)                    Mycophenolate mofetil (750 mg, 2 times/day)                     Immunoglobulin (500 mg/day, 4 days)
                                                             Methylprednisolone (Surgery and post1-2, 500 mg/day)                      Methylprednisolone (16 mg/day)                                  
                                                             Mycophenolate mofetil (Post1-2, 1,000 mg/day)                                                                                             
  3          Hemodialysis                                    Anti-human T Lymphocyte Porcine Immunoglobulin                            Tacrolimus (3.0 mg, 2 times/day)                                Methylprednisolone (500 mg/day, 3 days)
                                                             (Surgery and post1-2, 500 mg/day; post3-7, 250 mg/day)                    Mycophenolate mofetil (750 mg, 2 times/day)                     
                                                             Methylprednisolone (Surgery and post1-2, 500 mg/day)                      Methylprednisolone (16 mg/day)                                  
                                                             Mycophenolate mofetil (Post1-2, 1,000 mg, 2 times/day)                                                                                    

Pre2, 2 days prior to transplantation.

###### 

Multiplex-PCR amplification primers of the IGH complementarity-determining region 3 region.

  Primer name     Sequence (5′-3′)
  --------------- ------------------------------------------------
  IGHV1-18        CAGACGTGTGCTCTTCCGATCTAGAGAGTCACCATGACCACAGAC
  IGHV1-2/1-46    CAGACGTGTGCTCTTCCGATCTAGAGAGTCACCAKKACCAGGGAC
  IGHV1-24        CAGACGTGTGCTCTTCCGATCTAGAGAGTCACCATGACCGAGGAC
  IGHV1-3/1--45   CAGACGTGTGCTCTTCCGATCTAGAGAGTCACCATTACYAGGGAC
  IGHV1-69/1-f    CAGACGTGTGCTCTTCCGATCTAGAGAGTCACGATWACCRCGGAC
  IGHV1-8         CAGACGTGTGCTCTTCCGATCTAGAGAGTCACCATGACCAGGAAC
  IGH2-70/26/5    CAGACGTGTGCTCTTCCGATCTAGACCAGGCTCACCATYWCCAAGG
  IGHV3           CAGACGTGTGCTCTTCCGATCTAGGGCCGATTCACCATCTCMAG
  IGH4            CAGACGTGTGCTCTTCCGATCTAGCGAGTCACCATRTCMGTAGAC
  IGHV5-51        CAGACGTGTGCTCTTCCGATCTAGCAGCCGACAAGTCCATCAGC
  IGHV6-1         CAGACGTGTGCTCTTCCGATCTAGAGTCGAATAACCATCAACCCAG
  IGHV7-NEW       CAGACGTGTGCTCTTCCGATCTAGGACGGTTTGTCTTCTCCTTG
  IGHJ-Rev1       CTACACGACGCTCTTCCGATCTCTGAGGAGACRGTGACCAGGGTG
  IGHJ-Rev2       CTACACGACGCTCTTCCGATCTCTGAAGAGACGGTGACCATTGTC
  IGHJ-Rev3       CTACACGACGCTCTTCCGATCTCTGAGGAGACGGTGACCAGGGT
  IGHJ-Rev4       CTACACGACGCTCTTCCGATCTTGAGGAGACGGTGACCGTGGTC

IGHV, immunoglobulin heavy chain variable; IGHJ, IGH joining; f, forward; Rev, reverse; Annexing primer bases: R=A or G, Y=C or T, K=G or T M=A or C, W=A or T.

###### 

Sequence statistics for each sample.

  Case/time-point   Total reads (n)   Immune sequences (n)   In-frame sequences (n)   Out-of-frame sequences (n)   Total CDR3 sequences (n)   Unique CDR3 nt sequences (n)   Unique CDR3 AA sequences (n)
  ----------------- ----------------- ---------------------- ------------------------ ---------------------------- -------------------------- ------------------------------ ------------------------------
  Case 1                                                                                                                                                                     
    Pre1            435,064           431,037                340,034                  90,817                       285,020                    39,406                         32,744
    Post1           496,537           486,442                268,278                  217,707                      182,009                    18,828                         15,331
    Post7           403,593           398,636                220,842                  177,542                      150,370                    23,895                         20,310
  Case 2                                                                                                                                                                     
    Pre1            572,795           480,031                404,703                  75,068                       352,553                    51,913                         43,978
    Post1           650,859           356,884                242,488                  114,047                      191,181                    21,340                         17,431
    Post7           588,477           323,629                253,726                  69,720                       209,382                    29,920                         25,090
  Case 3                                                                                                                                                                     
    Pre1            922,607           313,193                240,813                  72,173                       202,578                    26,384                         21,771
    Post1           130,4368          393,937                300,335                  93,207                       257,911                    28,326                         22,837
    Post7           770,650           383,720                271,055                  112,466                      224,214                    24,027                         19,428

Pre1, 1 day prior to transplantation; post7, 7 days post transplantation; CDR3, complementarity-determining region 3; nt, nucleotide; AA, amino acid.

[^1]: Contributed equally
